Literature DB >> 15150086

The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia.

Yi Xu1, Takita Felder Sumter, Raka Bhattacharya, Abeba Tesfaye, Ephraim J Fuchs, Lisa J Wood, David L Huso, Linda M S Resar.   

Abstract

HMG-I/Y is overexpressed in human cancer, although a direct role for this gene in transformation has not been established. We generated transgenic mice with HMG-I targeted to lymphoid cells. All seven informative founder HMG-I mice developed aggressive lymphoma by a mean age of 4.8 months. Tumors express T-cell markers and are transplantable. We also demonstrate that HMG-I mRNA and protein are increased in human acute lymphocytic leukemia samples. Our results show that HMG-I functions as an oncogene and suggest that it contributes to the pathogenesis of leukemia and other cancers with increased HMG-I expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15150086     DOI: 10.1158/0008-5472.CAN-04-0044

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

Review 1.  The high mobility group A1 molecular switch: turning on cancer - can we turn it off?

Authors:  Tait H Huso; Linda M S Resar
Journal:  Expert Opin Ther Targets       Date:  2014-03-31       Impact factor: 6.902

2.  Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.

Authors:  Siong-Seng Liau; Stanley W Ashley; Edward E Whang
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

3.  Deregulation of common genes by c-Myc and its direct target, MT-MC1.

Authors:  Kenneth R Rogulski; Debra E Cohen; David L Corcoran; Panayiotis V Benos; Edward V Prochownik
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 4.  HMG chromosomal proteins in development and disease.

Authors:  Robert Hock; Takashi Furusawa; Tetsuya Ueda; Michael Bustin
Journal:  Trends Cell Biol       Date:  2006-12-13       Impact factor: 20.808

5.  HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells.

Authors:  Sugiko Watanabe; Yasuaki Ueda; Shin-ichi Akaboshi; Yuko Hino; Yoko Sekita; Mitsuyoshi Nakao
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

6.  The High Mobility Group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression.

Authors:  Paula Mussnich; Daniela D'Angelo; Vincenza Leone; Carlo Maria Croce; Alfredo Fusco
Journal:  Mol Oncol       Date:  2013-01-17       Impact factor: 6.603

7.  The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies?

Authors:  Joelle Hillion; Surajit Dhara; Takita Felder Sumter; Mita Mukherjee; Francescopaolo Di Cello; Amy Belton; James Turkson; Souyma Jaganathan; Linzhao Cheng; Zhaohui Ye; Richard Jove; Peter Aplan; Ying-Wei Lin; Kelsey Wertzler; Ray Reeves; Ossama Elbahlouh; Jeanne Kowalski; Raka Bhattacharya; Linda M S Resar
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

8.  High mobility group A1 protein acts as a new target of Notch1 signaling and regulates cell proliferation in T leukemia cells.

Authors:  Yang Xi; Yu-Sang Li; He-Bin Tang
Journal:  Mol Cell Biochem       Date:  2012-11-16       Impact factor: 3.396

9.  Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer.

Authors:  Joelle Hillion; Lisa J Wood; Mita Mukherjee; Raka Bhattacharya; Francescopaolo Di Cello; Jeanne Kowalski; Ossama Elbahloul; Jodi Segal; John Poirier; Charles M Rudin; Surajit Dhara; Amy Belton; Biju Joseph; Stanley Zucker; Linda M S Resar
Journal:  Mol Cancer Res       Date:  2009-11-10       Impact factor: 5.852

10.  STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway.

Authors:  Amy Belton; Lingling Xian; Tait Huso; Michael Koo; Li Z Luo; James Turkson; Brent D G Page; Patrick T Gunning; Guosheng Liu; David L Huso; Linda M S Resar
Journal:  Leuk Lymphoma       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.